Journal of Internal Medicine Concepts & Practice ›› 2024, Vol. 19 ›› Issue (02): 89-94.doi: 10.16138/j.1673-6087.2024.02.01
• Original article • Next Articles
ZHAO Huijin, JIN Zhen, ZHANG Yunxiang, WU Min, ZHENG Yu, WU Wen, SHEN Yang, CHEN Qiusheng, LI Junmin, CHEN Yu
Received:
2023-10-10
Online:
2024-04-30
Published:
2024-07-08
CLC Number:
ZHAO Huijin, JIN Zhen, ZHANG Yunxiang, WU Min, ZHENG Yu, WU Wen, SHEN Yang, CHEN Qiusheng, LI Junmin, CHEN Yu. Clinical efficacy of venetoclax combined with azacytidine in treatment of newly treated elderly patients with acute myeloid leukemia who were intolerant to intensive chemotherapy[J]. Journal of Internal Medicine Concepts & Practice, 2024, 19(02): 89-94.
[1] | Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2016[EB/M]. 2019. https://seer.cancer.gov/csr/1975_2016. |
[2] |
Wang R, Zeidan AM, Halene S, et al. Health care use by older adults with acute myeloid leukemia at the end of life[J]. J Clin Oncol, 2017, 35(30):3417-3424.
doi: 10.1200/JCO.2017.72.7149 pmid: 28783450 |
[3] |
Zeidan AM, Podoltsev NA, Wang X, et al. Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States[J]. Cancer, 2019, 125(23):4241-4251.
doi: 10.1002/cncr.32439 pmid: 31483484 |
[4] | Dennis M, Hills RK, Russell NH, et al. An evaluation of 17 years of low dose cytarabine as therapy for aml patients not fit for intensive treatment, including patients with adverse cytogenetics, shows improving survival, potential underutilisation and highlights the need for new therapy[J]. Blood, 2017, 130: 3874. |
[5] |
Amadori S, Suciu S, Selleslag D, et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy[J]. J Clin Oncol, 2016, 34(9):972-979.
doi: 10.1200/JCO.2015.64.0060 pmid: 26811524 |
[6] | DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia[J]. N Engl J Med, 2020, 383(7):617-629. |
[7] | Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy[J]. Blood, 2020, 135(24):2137-2145. |
[8] |
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20):2391-2405.
doi: 10.1182/blood-2016-03-643544 pmid: 27069254 |
[9] | 中华医学会血液学分会白血病淋巴瘤学组. 中国复发难治性急性髓系白血病诊疗指南(2021年版)[J]. 中华血液学杂志, 2021, 42(8): 624-627. |
[10] |
Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel[J]. Blood, 2017, 129(4): 424-447.
doi: 10.1182/blood-2016-08-733196 pmid: 27895058 |
[11] |
Ossenkoppele G, Löwenberg B. How I treat the older patient with acute myeloid leukemia[J]. Blood, 2015, 125(5): 767-774.
doi: 10.1182/blood-2014-08-551499 pmid: 25515963 |
[12] |
Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia[J]. Blood. 2006, 107(9):3481-3485.
doi: 10.1182/blood-2005-09-3724 pmid: 16455952 |
[13] |
Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry[J]. Blood, 2009, 113(18):4179-4187.
doi: 10.1182/blood-2008-07-172007 pmid: 19008455 |
[14] |
Bullinger L, Döhner K, Döhner H. Genomics of acute myeloid leukemia diagnosis and pathways[J]. J Clin Oncol, 2017, 35(9):934-946.
doi: 10.1200/JCO.2016.71.2208 pmid: 28297624 |
[15] | Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia[J]. Blood, 2008, 111(5):2776-2784. |
[16] |
Konopleva M, Letai A. BCL-2 inhibition in AML: an unexpected bonus?[J]. Blood, 2018, 132(10):1007-1012.
doi: 10.1182/blood-2018-03-828269 pmid: 30037885 |
[17] |
Chan SM, Thomas D, Corces-Zimmerman MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia[J]. Nat Med, 2015, 21(2):178-184.
doi: 10.1038/nm.3788 pmid: 25599133 |
[18] |
Winters AC, Gutman JA, Purev E, et al. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia[J]. Blood Adv, 2019, 3(20):2911-2919.
doi: 10.1182/bloodadvances.2019000243 pmid: 31648312 |
[19] | Matthews AH, Perl AE, Luger SM, et al. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia[J]. Blood, 2021; 138: 1246. |
[20] | Bouchard P, Brisebois-Boyer A, Beaudry A, et al. Efficacy, toxicity and cost of venetoclax-based combinations for the treatment of acute myeloid leukemia[J]. Blood, 2021,138 Suppl 1: 1253-1253. |
[21] |
Pollyea DA, Stevens BM, Jones CL, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia[J]. Nat Med, 2018, 24(12): 1859-1866.
doi: 10.1038/s41591-018-0233-1 pmid: 30420752 |
[22] | Pratz KW, Jonas BA, Pullarkat V, et al. Measurable residual disease response and prognosis in treatment-naïve acute myeloid leukemia with venetoclax and azacitidine[J]. J Clin Oncol, 2022, 40(8):855-865. |
[1] | YE Xiangjun, LU Xingguo. Interpretation of the 5th edition of the WHO classification of haematolymphoid tumours on MDS and AML [J]. Journal of Diagnostics Concepts & Practice, 2023, 22(05): 421-428. |
[2] | LU Hao, XI Huimin, LI Lu, CAI Xun. Low-dose sorafenib combined with all-trans retinoic acid induces differentiation of acute myeloid leukemia cells with wild type Fms like tyrosine kinase 3 [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(06): 428-434. |
[3] | JIANG Tianyi, LIU Fujia, CHENG Wenyan, ZHAO Huijin, SHEN Yang. Recombinant human thrombopoietin in treatment of acute myeloid leukemia thrombocytopenia after chemotherapy: a real-world study [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(04): 283-288. |
[4] | LUO Dongfeng, YOU Jianhua, LI Xiaoyang, LI Junmin, ZHANG Yunxiang. Study on the efficacy and safety of different induction therapies in newly diagnosed elderly patients with acute myeloid leukemia and intolerance of intensive chemotherapy [J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(03): 220-226. |
[5] | HUANG Lei, YE Chenjing, WU Chao, XU Wenbin, YU Qing, LI Junmin, YAN Hua. Clinical observation of the combination therapy of azacitidine and venetoclax in newly diagnosed, elderly patients with acute myeloid leukemia [J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(03): 178-182. |
[6] | GAO Yanting, ZHAO Jinyan, WANG Juan, LI Jia, XU Wen, LI Li, LIN Lihui. Analysis of bone marrow lymphocyte subsets in patients with acute myeloid leukemia and its clinical significance [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(04): 407-413. |
[7] | PENG Zhenping, XIANG Xixi, ZHANG Sujiang, LI Jiaming. Chronic neutrophilic leukemia with leukemia-like reaction as the first-onset manifestation: a report of 2 cases and literature review [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(02): 122-128. |
[8] | . [J]. Journal of Internal Medicine Concepts & Practice, 2019, 14(06): 361-365. |
[9] | . [J]. Journal of Internal Medicine Concepts & Practice, 2019, 14(02): 116-120. |
[10] | . [J]. Journal of Internal Medicine Concepts & Practice, 2018, 13(03): 175-180. |
[11] | . [J]. Journal of Internal Medicine Concepts & Practice, 2018, 13(02): 76-80. |
[12] | . [J]. Journal of Internal Medicine Concepts & Practice, 2017, 12(05): 344-350. |
[13] | WANG Shu, ZHANG Yunxiang, SUI Jingni, LU Jing, FAN Huiyong, WANG Chao, CHEN Bing.. Analysis of additional mutation pattern accompanied with CEBPA mutations in patients with the cytogenetically normal acute myeloid leukemia [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(05): 498-503. |
[14] | . [J]. Journal of Internal Medicine Concepts & Practice, 2017, 12(04): 293-297. |
[15] | . [J]. Journal of Internal Medicine Concepts & Practice, 2017, 12(03): 180-185. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||